Diffuse Large B Cell Lymphoma CD20 Positive Clinical Trial
Official title:
Randomized Phase III Study Using a Pet-driven Strategy and Comparing GA101 OR Rituximab Associated to a Chemotherapy Delivered Every 14 Days (ACVBP or CHOP) in DLBCL CD20+ Lymphoma Untreated Patients From 18 to 60 Presenting With 1 or More Adverse Prognostic Factors of the Age-adjusted IPI
This study is designed to investigate:
- the interest of a new monoclonal antibody (GA101)versus rituximab
- the interest of PET to identify early responders
Patients will receive either rituximab (standard treatment), either GA101 (study treatment),
according to the randomization arm.
The monoclonal antibody will be associated to a chemotherapy: CHOP or ACVBP according to
site's choice.A PET scan will be done before inclusion, after 2 chemotherapy cycles, and
after 4 chemotherapy cycles, to identify early patients responders, for who consolidation
with ASCT is not required.
n/a